GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

GSK Providing Refunds for 340B Overcharges During Q1 2020

Drug manufacturer GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

GSK posted a public notice about the repayments on the U.S. Health Resources and Services Administration web site this week. The refunds are on the type 2 diabetes treatment Tanzeum and five inhaled medicines for chronic obstructive pulmonary disease and/or asthma (Anoro, Arnuity, Breo, Incruse, and Trelegy). GSK said it determined that it owed the refunds after it recalculated ceiling prices for the products for the quarter.

The company said it would provide refunds directly to covered entities by check if the total amount owed for all applicable NDCs is equal to or greater than $100. The notice includes contact information for entities that may be owed less than $100 or that have questions.

Editor at Large | Website | + posts